TY  - JOUR 
AU  - Padilla-Galo, A.
AU  - Moya Carmona, I.
AU  - Ausín, P.
AU  - Carazo Fernández, L.
AU  - García-Moguel, I.
AU  - Velasco-Garrido, J.L.
AU  - Andújar-Espinosa, R.
AU  - Casas-Maldonado, F.
AU  - Martínez-Moragón, E.
AU  - Martínez Rivera, C.
AU  - Vera Solsona, E.
AU  - Sánchez-Toril López, F.
AU  - Trisán Alonso, A.
AU  - Blanco Aparicio, Marina
AU  - Valverde-Monge, M.
AU  - Valencia Azcona, B.
AU  - Palop Cervera, M.
AU  - Nuevo, J.
AU  - Sánchez Tena, J.
AU  - Resler, G.
AU  - Luzón, E.
AU  - Levy Naon, A.
PY  - 2023
SN  - 1465-993X
UR  - http://hdl.handle.net/20.500.11940/21061
AB  - BACKGROUND: The ORBE II study aimed to describe the characteristics and clinical outcomes of adult patients with severe eosinophilic asthma (SEA) treated with benralizumab in a real-world setting in Spain. METHODS: ORBE II (NCT04648839) was an...
LA  - eng
KW  - Adult
KW  - Humans
KW  - Female
KW  - Middle Aged
KW  - Male
KW  - Anti-Asthmatic Agents
KW  - Retrospective Studies
KW  - Disease Progression
KW  - Asthma
KW  - Pulmonary Eosinophilia
KW  - Chronic Disease
KW  - Adrenal Cortex Hormones
KW  - Sinusitis
TI  - Achieving clinical outcomes with benralizumab in severe eosinophilic asthma patients in a real-world setting: orbe II study
DO  - 10.1186/s12931-023-02539-7
T2  - Respiratory research
M2  - 235
KW  - AS A Coruña
KW  - CHUAC
VL  - 24
ER  -